Search

Your search keyword '"Anwer, Faiz"' showing total 9 results
Start Over Author "Anwer, Faiz" Journal bone marrow transplantation
9 results on '"Anwer, Faiz"'

1. The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma

Author

Aleixo, Gabriel F. P., primary, Wei, Wei, additional, Chen, Po-Hao, additional, Gandhi, Namita S., additional, Anwer, Faiz, additional, Dean, Robert, additional, Hamilton, Betty K., additional, Hill, Brian T., additional, Jagadeesh, Deepa, additional, Khouri, Jack, additional, Pohlman, Brad, additional, Sobecks, Ronald, additional, Winter, Allison, additional, Caimi, Paolo, additional, and Majhail, Navneet S., additional

Published
2023
Full Text
View/download PDF

2. On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone

Author

Hubben, Anne, primary, Dima, Danai, additional, Atieh, Tahani, additional, Chaulagain, Chakra, additional, Faiman, Beth, additional, Ferraro, Christina, additional, Mazzoni, Sandra, additional, Williams, Louis, additional, Samaras, Christy, additional, Valent, Jason, additional, Sauter, Craig, additional, Anwer, Faiz, additional, and Khouri, Jack, additional

Published
2023
Full Text
View/download PDF

3. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

Author

Mian, Agrima, primary, Wei, Wei, additional, Hamilton, Betty K., additional, Winter, Allison M., additional, Khouri, Jack, additional, Pohlman, Brad, additional, Gerds, Aaron T., additional, Jagadeesh, Deepa, additional, Anwer, Faiz, additional, Kalaycio, Matt, additional, Dean, Robert M., additional, Sobecks, Ronald, additional, Caimi, Paolo F., additional, Hill, Brian T., additional, and Majhail, Navneet S., additional

Published
2023
Full Text
View/download PDF

4. Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant

Author

Hegde, Pranay S., primary, Rybicki, Lisa, additional, Serafino, Sheila, additional, Bernhard, Laura, additional, Corrigan, Donna, additional, Anwer, Faiz, additional, Kalaycio, Matt, additional, Sobecks, Ronald M., additional, Jagadeesh, Deepa, additional, Hill, Brian T., additional, Dean, Robert M., additional, Khouri, Jack, additional, Winter, Allison M., additional, Pohlman, Brad, additional, Majhail, Navneet S., additional, and Hamilton, Betty K., additional

Published
2022
Full Text
View/download PDF

5. Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan

Author

Khan, Maryam, primary, Iftikhar, Raheel, additional, Ghafoor, Tariq, additional, Hussain, Fayyaz, additional, Chaudhry, Qamar un Nisa, additional, Mahmood, Syed Kamran, additional, Shahbaz, Nighat, additional, Khan, Mehreen Ali, additional, Khattak, Tariq Azam, additional, Shamshad, Ghassan Umair, additional, Rehman, Jahanzeb, additional, Ali, Sundas, additional, Shah, Zunaira, additional, Rafae, Abdul, additional, Farhan, Muhammad, additional, Anwer, Faiz, additional, and Ahmed, Parvez, additional

Published
2020
Full Text
View/download PDF

6. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review

Author

bin Riaz, Irbaz, primary, Umar, Muhammad, additional, Zahid, Umar, additional, Husnain, Muhammad, additional, Iftikhar, Ahmad, additional, McBride, Ali, additional, Bilal, Jawad, additional, Javed, Asad, additional, Akbar, Sara, additional, Singh, Parminder, additional, Ali, Zeeshan, additional, Sipra, Qurat Ul Ain Riaz, additional, Gondal, Farva Razia, additional, Ahman, Frederick, additional, and Anwer, Faiz, additional

Published
2018
Full Text
View/download PDF

7. Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan

Author

Khan, Maryam, Iftikhar, Raheel, Ghafoor, Tariq, Hussain, Fayyaz, Chaudhry, Qamar un Nisa, Mahmood, Syed Kamran, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq Azam, Shamshad, Ghassan Umair, Rehman, Jahanzeb, Ali, Sundas, Shah, Zunaira, Rafae, Abdul, Farhan, Muhammad, Anwer, Faiz, and Ahmed, Parvez

Abstract

Management of rare hematological disorders pose unique diagnostic and therapeutic challenges due to unusual occurrence and limited treatment options. We retrospectively identified 45 patients receiving matched related donor transplant for rare hematological disorders from 2006 to 2019. Patients were divided into two groups (1) malignant and (2) non malignant. The malignant disorder group included four patients while the nonmalignant group included 41 patients divided into immune dysregulation (n= 23), bone marrow failure (n= 10), metabolic (n= 5), and bleeding diathesis (n= 3). Twenty-six (57.8%) patients received myeloablative conditioning (MAC) and 16 (35.6%) received reduced intensity conditioning (RIC), while 3 (6.6%) patients with severe combined immunodeficiency received stem cell infusion alone without conditioning. The cumulative incidence (CI) of grade II–IV acute GVHD (aGVHD) was 39.1% (n= 18) and chronic GVHD (cGVHD) 15.2% (n= 7). There was no primary graft failure while CI of secondary graft failure was 9%. Overall survival (OS) and disease-free survival (DFS) was 82.2% and 77.8% respectively. Group wise OS was 75% in the malignant group, 82.6% in the immune dysregulation group, 80% in patients with metabolic disorders and bone marrow failure, while 100% in patients with bleeding diathesis. This retrospective analysis shows that hematopoietic stem cell transplant can be a feasible treatment option for rare hematological disorders.

Published
2021
Full Text
View/download PDF

9. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review

Author

Riaz, Irbaz, Umar, Muhammad, Zahid, Umar, Husnain, Muhammad, Iftikhar, Ahmad, McBride, Ali, Bilal, Jawad, Javed, Asad, Akbar, Sara, Singh, Parminder, Ali, Zeeshan, Sipra, Qurat Ul Ain Riaz, Gondal, Farva, Ahman, Frederick, and Anwer, Faiz

Abstract

Approximately 20–30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results